UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Condition:   Thyroid Cancer
Interventions:   Drug: Lenvatinib;   Drug: Everolimus
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2017

http://ift.tt/2pc2f4G


http://ift.tt/2pcgjuV